Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02519270 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
A Phase 1 study, sponsored by Spectrum Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT02519270 is a Phase 1 study that was terminated before completion, run by Spectrum Pharmaceuticals. The registered enrollment target is 62 participants.
The verdict
NCT02519270, a Phase 1 study, was terminated before completion, sponsored by Spectrum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma (NHL)
Interventions
- BIOLOGICAL IGN002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2016-05-01 |
| Est. Completion | 2018-05-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02519270
The ClinicalTrials.gov registry entry for NCT02519270 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IGN002 is the first listed.
NCT02519270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02519270 about?
NCT02519270 is a clinical study titled "Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects". A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma (NHL)
What is the current status of trial NCT02519270?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2016-05-01. Estimated completion is 2018-05-04.
What interventions are being tested in trial NCT02519270?
The interventions under investigation include: IGN002 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02519270?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.